Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jul 20, 2021 9:46am
186 Views
Post# 33574577

RE:RE:Ate'$ next mission

RE:RE:Ate'$ next missionThere are essentially no positive catalysts priced in to the stock. Which means that when those events come to market, the stock will react to it fully and price it in accordingly (contrary to the typical stock market function of buy the rumor, sell the news).
The data from the trials suggests a high probability of a successful outcome.
Nuance agrees. Consider the amount of due diligence they have conducted, which resulted in them paying $20m upfront for a product that doesn't exist on the market yet. 
With all due respect to all retail investors, the amount of wotk Nuance would have done in determining a decision for an investment, is far superior to any work done by retail investors.
They don't make decisions based on stock price, they make decisions based on the actual business, facts and fundamentals.
They put up millions in Antibe.
Keep that in mind next time you feel panic about the stock.

Amigo11 wrote: With about $1.85 in cash per share ,investors are really paying $1.40 per share for all the upside of ATE.As we didn't have any cash per share for most of our existence,a prospective investor hasnt paid this little for all the upsidd in a long time.


<< Previous
Bullboard Posts
Next >>